Atria Wealth Solutions Inc. Lowers Stake in Bruker Co. (NASDAQ:BRKR)

Atria Wealth Solutions Inc. decreased its position in shares of Bruker Co. (NASDAQ:BRKR) by 4.9% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 3,704 shares of the medical research company’s stock after selling 192 shares during the period. Atria Wealth Solutions Inc.’s holdings in Bruker were worth $272,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Lindbrook Capital LLC boosted its holdings in shares of Bruker by 68.2% during the fourth quarter. Lindbrook Capital LLC now owns 360 shares of the medical research company’s stock worth $26,000 after purchasing an additional 146 shares during the last quarter. GAMMA Investing LLC purchased a new stake in Bruker in the 4th quarter valued at about $33,000. VisionPoint Advisory Group LLC increased its stake in shares of Bruker by 145.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 512 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 303 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Bruker by 53.3% during the 3rd quarter. Fifth Third Bancorp now owns 541 shares of the medical research company’s stock worth $34,000 after acquiring an additional 188 shares during the period. Finally, Life Planning Partners Inc acquired a new stake in shares of Bruker in the fourth quarter worth approximately $44,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BRKR has been the topic of a number of recent analyst reports. Citigroup increased their price target on shares of Bruker from $80.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, February 14th. The Goldman Sachs Group boosted their price target on Bruker from $66.00 to $74.00 and gave the company a “sell” rating in a research report on Wednesday, April 10th. Stifel Nicolaus raised their price objective on Bruker from $63.00 to $81.00 and gave the stock a “hold” rating in a report on Wednesday, February 14th. JPMorgan Chase & Co. upgraded Bruker from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $60.00 to $90.00 in a report on Wednesday, February 14th. Finally, UBS Group raised their price target on shares of Bruker from $94.00 to $102.00 and gave the company a “buy” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $84.86.

Bruker Trading Down 0.8 %

BRKR opened at $73.70 on Thursday. The firm’s 50 day moving average is $86.72 and its 200-day moving average is $75.43. Bruker Co. has a 52-week low of $53.79 and a 52-week high of $94.86. The company has a quick ratio of 0.91, a current ratio of 1.81 and a debt-to-equity ratio of 0.95. The firm has a market capitalization of $10.71 billion, a P/E ratio of 26.80, a P/E/G ratio of 1.73 and a beta of 1.22.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Thursday, May 2nd. The medical research company reported $0.53 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.07. The firm had revenue of $721.70 million for the quarter, compared to the consensus estimate of $729.88 million. Bruker had a net margin of 13.38% and a return on equity of 27.31%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.64 EPS. Analysts expect that Bruker Co. will post 2.82 EPS for the current fiscal year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $0.20 dividend on an annualized basis and a yield of 0.27%. Bruker’s dividend payout ratio (DPR) is presently 7.27%.

Insiders Place Their Bets

In other news, Director Hermann Fritz Requardt sold 15,000 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $90.06, for a total transaction of $1,350,900.00. Following the completion of the transaction, the director now directly owns 23,147 shares in the company, valued at approximately $2,084,618.82. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 28.30% of the stock is owned by company insiders.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.